The biotechnology sector was rocked last week by the news President-elect Donald Trump has nominated Robert F Kennedy Junior (RFK Jr) as secretary of the Department of Health and Human Services.
RFK Jr’s controversial views on healthcare, including vaccine skepticism, potential reforms to FDA oversight, and plans to remove fluoride from public water supply, have raised concerns about disruptions to the FDA and biopharma industry.
Shares of drugmakers fell on the announcement last Friday, notably vaccine makers including Moderna, Pfizer and Novavax.
Analysts at Baird expect that the theme of “what would RFK Jr do” will dominate investor discussions for the foreseeable future until there is clarity on whether his nomination will face obstacles.
“RFK Jr's controversial stances on a variety of healthcare-related topics has, at minimum, injected unprecedented uncertainty into the sector, as this role has formal oversight of Centers for Medicare & Medicaid Services (CMS), the Food and Drug Administration (FDA), the Centers for Disease Control (CDC) and Prevention, and the National Institutes of Health (NIH) and impacts every part of the sector,” the analysts wrote in a note to client.
“RFK Jr has previously been vocally critical of vaccines and promised to clear corruption within the FDA, though his focus appears to be primarily related to the food side of the agency, and he said he would not ban any vaccines from the market.”
Analysts also noted RKF’s intention to pause drug development and infectious disease research in favor of chronic disease “seems like a far-fetched ambition.”
They concluded: “Our takeaway is the nomination introduces substantial uncertainty to the future direction of the FDA and the biopharma industry, which makes it a tough investment thesis, especially in the current higher rate environment.”